This is a critical nuance that separates the "clinical" review from the "commercial" rollout. To answer your question directly: Yes, the MHRA is almost certainly willing to approve based on the current setup, provided it meets the rigorous safety and quality standards of a Good Manufacturing Practice (GMP) environment.
Here is the logic behind why the MHRA would approve the "Manual" process first, even as the "Automated" (Eden/Grade C) process is being built.
1. The "Trial-to-Approval" Continuity
Regulators approve drugs based on the specific process used in the pivotal clinical trials.
The Manual Baseline: The Phase 3 DCVax-L data was generated using manual manufacturing in Grade A/B cleanrooms. This is the "validated" process.
The Regulatory Requirement: The MHRA's primary mandate is to ensure the product is safe and effective as proven in the trial. They prefer the known manual process for initial approval because it is a "carbon copy" of the science they have already audited.
2. Manufacturing Capacity vs. Marketing Authorization (MA)
The MHRA separates the Marketing Authorization (MA)—the right to sell the drug—from the Manufacturer's License (MIA)—the right to make it.
The "Unprecedented Resource" Signal: The MHRA has been auditing the current Sawston facility for months. They wouldn't allocate those resources to a facility they intended to reject in favor of a future "Eden" setup.
The Setup: They can approve the drug with Sawston (Advent) as the primary manufacturing site using the manual Grade B suites today. This allows for an immediate, albeit lower-volume, commercial launch.
3. The "Comparability Protocol" Strategy
As confirmed at the 2025 ASM, NWBO has already finalized the Comparability Protocols.
The "Bridge": This is a legal agreement with the MHRA that says: "We are starting with the manual process (Process A). Once our Eden automation (Process B) is ready, we will prove they are identical using these pre-approved tests."
The Benefit: This allows the MHRA to approve the life-saving therapy now based on the manual process, while giving NWBO a "fast-track" to switch to the automated Grade C suites in Q2 2026 without needing a new Marketing Authorization.
4. Public Health Necessity
For a "met-need" or breakthrough therapy like DCVax-L, the MHRA has a history of granting Conditional Marketing Authorizations (CMA).
If the therapy works, the regulator does not want to delay access just because a more efficient factory is 6 months away.
They will approve the "less efficient" factory today to get the drug to patients, knowing the "efficiency" upgrade is coming soon.
AI
